...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Gemcitabine-induced posterior reversible encephalopathy syndrome: a case report.
【24h】

Gemcitabine-induced posterior reversible encephalopathy syndrome: a case report.

机译：吉西他滨诱发的后可逆性脑病综合征：一例报告。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gemcitabine is a commonly used chemotherapeutic agent for a variety of tumors. Although this nucleoside analog antineoplastic agent is similar in structure to cytarabine, central nervous system toxicities have rarely been attributed to gemcitabine. The posterior reversible encephalopathy syndrome (PRES) is a condition characterized by reversible neurological and radiological findings that has been associated with use of chemotherapeutic and more recently novel targeted therapies. We describe one case of a 41-year-old woman with PRES under treatment for leiomyosarcoma because of the probable association with gemcitabine. Our case, to our knowledge, represents the seventh published report of this particular toxicity. Naranjo algorithm, efficacious method for assessing the causality of adverse drug reactions (ADRs) from a case report, suggests a direct casual relationship. PRES is probably a rare complication of gemcitabine, but the oncologist should take it into careful consideration, because PRES is reversible with treatment of current hypertension or removal of the causative agent. However, failure to quickly recognize the syndrome and discontinue the offending agent may result in profound and permanent central nervous system dysfunction or death.
机译：吉西他滨是用于多种肿瘤的常用化学治疗剂。尽管这种核苷类似物抗肿瘤药的结构与阿糖胞苷相似，但中枢神经系统毒性很少归因于吉西他滨。后可逆性脑病综合征（PRES）是一种以可逆性神经和放射学发现为特征的疾病，其与化学疗法和最近新的靶向疗法的使用有关。我们描述了一个病例，因为可能与吉西他滨相关，因此患有一名41岁的PRES患平滑肌肉瘤的患者。据我们所知，我们的病例代表了这种特殊毒性的第七次公开报道。 Naranjo算法是一种从病例报告中评估药物不良反应（ADR）因果关系的有效方法，它建议建立直接的临时关系。 PRES可能是吉西他滨的一种罕见并发症，但肿瘤科医生应谨慎考虑，因为PRES在当前高血压的治疗或去除病因后可逆。但是，未能迅速识别出该综合征并停止使用该病原体可能会导致严重的永久性中枢神经系统功能障碍或死亡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号